FDA Abbreviated New Drug Application (ANDA) Process Explained: How Generics Beat Brand Names
The FDA's Abbreviated New Drug Application (ANDA) process allows generic drugs to gain approval by proving equivalence to brand names, skipping costly clinical trials. This guide explains the Hatch-Waxman Act, bioequivalence requirements, and how ANDAs drive down healthcare costs.
FDA's 180-Day Exclusivity: How First Generic Applicants Gain Market Advantage
FDA's 180-day exclusivity rewards the first generic drug maker to challenge a patent, but delays and deals have turned it into a tool for market control. Here's how it works - and why reform is coming.